Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
260.00    0.00 (0.00%)
Bid:
256.00
Ask:
265.00
Spread: 9.00 (3.516%)
Market Cap: £232.84m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Interim Management Statement

6 Nov 2014 07:00

RNS Number : 2805W
Wilmington Group Plc
06 November 2014
 



6 November 2014

 

Wilmington Group plc

 

Interim Management Statement

 

 

Wilmington Group plc ("Wilmington" or "the Group"), the provider of Information, Compliance and Education to professional markets, presents its Interim Management Statement for the period from 1 July 2014, based on the results for the three months ended 30 September 2014 with comments reflecting trading to date. This statement is also being made at the Group's Annual General Meeting being held today.

 

Trading Update

 

The Group has made a good start to the year with revenue up during the three months ended 30 September 2014 despite adverse currency effects. Our business is performing well against the comparative period in 2013 and in line with our expectations.

 

Banking & Compliance: ICT (compliance training) continues to secure major training programmes from international banks, and this has resulted in strong revenue growth during the three months ended 30 September 2014. As previously reported we have invested in additional resource to support the business' expansion, and despite this contribution to profits has grown strongly. AMT (banking training) which delivers most of its revenue and contribution during the summer months has again delivered revenue and contribution in line with our expectations, with a particularly strong performance from its graduate programmes in Hong Kong. This division does have significant international operations and has been adversely impacted by movements in exchange rates.

 

Pensions & Insurance: This division continues to deliver revenue and contribution growth and has maintained its high margins. ICP (company credit reporting), which had a record year last year, has seen a small fall in demand but has mitigated this to a large extent by good cost control. This division also has significant international operations and has therefore also been adversely impacted by movements in exchange rates year on year.

 

Healthcare: This division benefitted from a significant investment last year with five senior appointments which is reflected in a higher overhead base in the first quarter compared to the same period in 2013. We have seen positive overall revenue growth compared to the same period in the prior year despite the negative impact of the Euro on our French language medical news agency, Agence de Presse Médicale. It is too early to see if the challenging conditions have abated but we are encouraged by the good start to the year.

 

Legal: The Legal division has continued to experience challenging conditions although the rate of decline has moderated and some areas, particularly Bond Solon, continue to see growth. Our lower cost base has meant that the performance from the division has improved compared to the same period in 2013.

 

Business Intelligence: As anticipated, revenue is up slightly on the same period in 2013. This combined with a lower cost base resulted in contribution in line with our expectations and up on the same period in 2013.

 

Accountancy: The division has enjoyed a strong start to the year reflecting inter alia demand for face to face public course training. This additional revenue is reflected in the division's pleasing overall increase in contribution due to the operational gearing of the business.

 

Management

As previously announced, Pedro Ros assumed the role of Chief Executive on 1 October 2014 having joined the Board on 14 July 2014.

Net Debt

The Group's cash position remains robust benefitting from strong operational cashflows. Net debt as at 30 September 2014 was £32.6m (30 September 2013: £39.2m).

 

Outlook

The overall trading background has not changed significantly since the full year 2014 results announcement and the business is on track to meet our expectations for the full year.

We are progressing well on our review of the businesses and expect to provide an update during December 2014.

 

 

-End-

 

 

 

For further information, please contact:

Wilmington Group plc

020 7422 6800

Pedro Ros, Chief Executive

Tony Foye, Chief Finance Officer

FTI Consulting

020 3727 1000

Charles Palmer / Emma Appleton

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSUGGRCGUPCGMA
Date   Source Headline
4th Mar 20257:00 amRNSTransaction in Own Shares
3rd Mar 20254:39 pmRNSDirector/PDMR Shareholding
3rd Mar 20254:35 pmRNSDirector/PDMR Shareholding
3rd Mar 20257:00 amRNSTransaction in Own Shares
28th Feb 20257:00 amRNSTransaction in Own Shares
27th Feb 20257:00 amRNSShare repurchase programme
17th Feb 20257:00 amRNSHalf-year Report
17th Jan 20259:42 amRNSNotice of Half Year Results
4th Dec 20247:00 amRNSDirector/PDMR Shareholding
28th Nov 202411:03 amRNSResult of AGM
25th Nov 20241:37 pmRNSHolding(s) in Company
20th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20243:13 pmRNSDirector/PDMR Shareholding
1st Nov 20247:00 amRNSTotal Voting Rights
25th Oct 20247:00 amRNSAcquisition of Phoenix Health & Safety
21st Oct 20241:47 pmRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSIssue of Ordinary Shares
1st Oct 20247:00 amRNSDirector/PDMR Shareholding
16th Sep 20247:00 amRNSFinancial results for the year ended 30 June 2024
2nd Sep 20247:00 amRNSTotal Voting Rights
29th Jul 20248:59 amRNSDirector Declaration
24th Jul 20247:00 amRNSTrading Statement
10th Jul 202410:57 amRNSHolding(s) in Company
2nd Jul 20242:51 pmRNSTotal Voting Rights - Replacement
1st Jul 20247:00 amRNSTotal Voting Rights
27th Jun 20247:00 amRNSUK Healthcare Business sold for £26.3 million
26th Apr 20247:46 amRNSAPM sold for EUR 26 million
23rd Apr 20243:49 pmRNSSAYE and Director/PDMR Shareholding
19th Feb 20247:00 amRNSHalf-year Report
6th Feb 202411:12 amRNSBoard Changes
1st Feb 20247:00 amRNSMiExact sold for £9.6 million
18th Jan 202411:00 amRNSNotice of Half Year Results
2nd Jan 20247:00 amRNSTotal Voting Rights
18th Dec 20232:42 pmRNSIssue of ordinary shares
11th Dec 20233:54 pmRNSIssue of Ordinary Shares
7th Dec 20232:25 pmRNSIssue of Ordinary Shares
1st Dec 202311:40 amRNSDirector/PDMR Shareholding
30th Nov 20232:53 pmRNSIssue of Ordinary Shares
23rd Nov 20239:49 amRNSAcquisition of Astutis Ltd by Wilmington plc
22nd Nov 20232:37 pmRNSResult of AGM
1st Nov 20237:00 amRNSTotal Voting Rights
3rd Oct 20232:52 pmRNSHolding(s) in Company
2nd Oct 202311:57 amRNSDirector/PDMR Shareholding
2nd Oct 202310:19 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSIssue of Ordinary Shares
25th Sep 20236:06 pmRNSAmendment to Financial Results announcement
25th Sep 20237:00 amRNSFinancial results for the year ended 30 June 2023
26th Jul 20237:00 amRNSTrading Statement
11th Apr 20237:00 amRNSSAYE and Director/PDMR Shareholding
7th Mar 20235:32 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.